Low- and middle-income countries will be able to purchase an effective preventative at a reduced price. The arrangements may help stem the epidemic 40 years after it began.
Tag: Gilead Sciences Inc
Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.
Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.
Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
Gilead Shot Provides Total Protection From HIV in Trial of Young African Women
An injection given just twice a year could herald a breakthrough in protecting the population that has the highest infection rates.
F.D.A. Approves Remdesivir for Patients Not Hospitalized
The treatment must be given via intravenous infusion over three consecutive days, generally at a hospital or clinic.
Shot to Prevent H.I.V. Works Better Than Daily Pill in Women
Researchers ended a clinical trial of the drug early because the results were so convincing. The more effective drug would be given in six injections a year instead of as 365 daily pills.
Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial
Critics said the study, sponsored by the W.H.O., was too poorly conducted to be definitive.
Remdesivir Coronavirus Trial: Federal Scientists Finally Publish Data
A clinical trial led to the authorization of the only drug shown to work in Covid-19 patients. But until now, few experts had seen the numbers.